Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia

Blood

Volumn 90, Issue 3, 1997, Pages 1226-1232

  Dibenedetto, Salvatore P ^a   Lo Nigro, Luca ^b   Mayer, Sharon Pine ^b   Rovera, Giovanni ^b   Schilirò, Gino ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE REARRANGEMENT; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0030789005     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.3.1226     Document Type: Article

References (35)

1. d'Auriol L. Macintyre E, Galibert F, Sigaux F: In vitro amplification of T cell gene rearrangements: A new tool for the assessment of minimal residual disease in acute lymphocytic leukemias. Leukemia 3:155, 1989
2. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane S, Lange B, Tsujimoto Y, Caton A, Rovera G: Detection of minimal disease in hematopoietic malignancies of the B cell lineage using third-complementary-determining region (CDR-III) - specific probes. Proc Natl Acad Sci USA 86:5123, 1989
3. Hansen-Hagge TE, Yokota S, Bartram CR: Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T cell receptor γ sequences. Blood 74:1762, 1989
4. Deane M, McCarthy KP, Wiedemann LM, Norton JD: An improved method for detection of B-lymphoid clonality by polymerase chain reaction. Leukemia 5:726, 1991
5. Brisco MJ, Condon J, Sykes PJ, Neoh SH, Morley AA: Detection and quantitation of neoplastic cells in acute lymphocytic leukemia by use of the polymerase chain reaction. Br J Haematol 79:211, 1991
6. Yamada M, Wasserman R, Lange B. Reichard BA, Womer RB, Rovera G: Minimal residual disease in childhood B lineage lymphocytic leukemia: Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323:448, 1990
7. Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavackar A, Kleihauer E, Bartram CR: Use of polymerase chain reaction to monitor minimal residual disease in acute lymphocytic leukemia patients. Blood 77:331, 1991
8. Nizet Y, Martiat P, Vaerman JL, Philippe M, Wildmann C, Staelens JP, Cornu G, Ferrant A, Michaux JL, Sokal G: Follow up of residual disease in B-lineage ALL using a simplified PCR strategy: Evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 79:205, 1991
9. Neale GAM, Menarguez J, Kitchingman GR, Fitzgerald TJ, Koehler M, Mirro J Jr, Goorha RM: Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 78:739, 1991
10. Nizet Y. Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martial P: Long term follow up of residual disease in ALL patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82:1618, 1993
11. Ito Y, Wasserman R, Galili N, Reichard B, Shane S, Lange B, Rovera G: Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphocytic leukemia. J Clin Oncol 11:546, 1993
12. Wasserman R, Galili N, Ito Y, Silver JH, Reichard BA. Shane S, Womer RB, Lange B. Rovera G: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 10:1879, 1992
13. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R. Toogood I, Waters K, Tauro G, Ekert H: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343:196, 1994
14. Radich JP, Gehly G, Gooley T. Bryant E, Clift RA, Collins S, Edmands S, Kirk K, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED: Polymerase chain reaction of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 85:2632, 1995
15. Pui CH, Behm FG, Crist WM: Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343, 1993
16. Pullen DJ, Crist WM, Falletta JM, et al: A Pediatric Oncology Group classification protocol for acute lymphoblastic leukemia (AlinC 13): Immunologic phenotypes and correlation with treated results, in Murphy S, Gilbert J (eds): Leukemia Research: Advances in Biology and Treatment. New York, NY, Excerpta Medica, 1983
17. Smith M, Arthur D, Camitta B, Carrol AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18, 1996
18. Reiter A, Schrappe M, Ludwig WD: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
19. Schorin M, Blattner S, Gelber R: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
20. Breit TM, Wolvers-Tettero ILM, Beishuizen A, Verhoeven MAJ, Wering ER, van Dongen JJM: Southern blot patterns, frequencies, and junctional diversity of T-cell receptor-δ gene rearrangements in acute lymphoblastic leukemia. Blood 82:3063, 1993
21. Breit TM, Wolvers-Tettero ILM, Hahlen K, van Wering ER, van Dongen JJM: Extensive junctional diversity of γδ T-cell receptors expressed by T-cell acute lymphoblastic leukemias: Implications for the detection of minimal residual disease. Leukemia 5:1076, 1991
22. H gene rearrangement events can modify the immunoglobulin heavy chain during progression of B-lineage acute lymphoblastic leukemia. Blood 79:223, 1992
23. Biondi A, Yokota S, Hansen-Hagge TE, et al: Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6:282, 1992
24. Saiki RK, Gelfand DM, Stoffel S, Scharf SJ. Miguchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487, 1988
25. Taylor JJ, Rowe D, Kylefjord H, Chessells J, Katz F, Proctor SJ, Middleton PG: Characterization of non-concordance in the T-cell receptor γ chain genes at presentation and clinical relapse in acute lymphoblastic leukemia. Leukemia 8:60, 1994
26. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio G, Gemperlein I, Griffin C, Emanuel B, Finan J, Nowel PC, Rovera G: Growth factor requirements of childhood acute leukemia: Establishment of GM-CSF-dependent cell lines. Blood 70:192, 1987
27. Cox DR, Oakes D: Analysis of Survival Data, New York, NY, Chapman & Hall, 1984
28. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
29. H-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood 81:775, 1993
30. Steenbergen EJ, Verhagen OJHM, Leeuwen EF, Berg H, Borne AEGK, School CE: Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: Implications for monitoring minimal residual disease. Blood 86:692, 1995
31. Ghali DW, Panzer S, Fischer S, Tinta AA, Haas OA, Kovar H, Gadner H, Grumayer ERP: Heterogeneity of the T-cell receptor δ gene indicating subclone formation in acute precursor B-cell leukemias. Blood 85:2795, 1995
32. Privitera E, Rivolta A, Ronchetti D, Mosna G. Giudici G, Biondi A: Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1: 19)-positive acute lymphoblastic leukaemia. Br J Haematol 92:653, 1996
33. Cimino G, Elia L, Rivolta A, Rapanotti MC, Rossi V, Alimena G, Annino L, Canaani E, Lo Coco F, Biondi A: Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4-positive acute lymphoblastic leukaemia. Br J Haematol 92:659, 1996
34. Neale GAM, Menarguez J, Kitchingman GR, Fitzgerald TJ, Koehler M, Mirro J, Goorha RM: Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 78:739, 1991
35. Cavè H, Guidai C, Rohrlich P, Defau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandhamp B: Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of T-cell receptor genes. Blood 83:1892, 1994